IIT Bhubaneswar and ILS Transfer Novel TB Vaccine Technology to TechInvention

24 November 2025

The Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, along with the National Research Development Corporation, have signed a Quadripartite License Agreement with TechInvention Lifecare Limited for the technology transfer and future commercialization of a novel TB vaccine candidate titled “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”

The HSP Subunit Vaccine candidate, jointly developed by IIT Bhubaneswar and ILS, is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

Download the full press release here.

Source: IIT Bhubaneswar